Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial

Bibliographic Details
Main Authors: Orbai, AM, Coates, LC, Deodhar, A, Helliwell, P, Ritchlin, CT, Kollmeier, A, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C
Format: Conference item
Language:English
Published: BMJ Publishing Group 2021

Similar Items